Ocriplasmin - ThromboGenics

Drug Profile

Ocriplasmin - ThromboGenics

Alternative Names: A-01016; Jejetrea®; Jetrea; Microplasmin; Recombinant human microplasmin; Recombinant microplasmin; THR-409

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Leuven
  • Developer Alcon; ThromboGenics; University of Leuven
  • Class Anti-ischaemics; Eye disorder therapies; Peptide fragments; Serine endopeptidases
  • Mechanism of Action Antiplasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Retinal disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Marketed Retinal disorders
  • Phase II Diabetic retinopathy
  • Preclinical Retinal vein occlusion
  • Suspended Deep vein thrombosis; Peripheral arterial occlusive disorders; Stroke
  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 08 Dec 2017 ThromboGenics discontinues enrolment in the phase II CIRCLE trial for Diabetic Retinopathy (Non-proliferative) due to slow recruitment of patients
  • 28 Sep 2017 ThromboGenics launches 'already-diluted' formulation of Ocriplasmin for the treatment of retinal disorders, in USA
  • 18 Sep 2017 ThromboGenics to regain global rights of ocriplasmin from Alcon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top